RGLS | tickerfilter.com

Fundamental analysis

33%

Profitability 43%

Dept financing 21%

Liquidity 37%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.65%

1 Month

0.65%

3 Months

-1.91%

6 Months

-24.51%

1 Year

19.38%

2 Year

31.62%

Key data

Stock price

$1.56

P/E Ratio

0.00

DAY RANGE

$1.52 - $1.58

EPS

$0.00

52 WEEK RANGE

$1.22 - $3.79

52 WEEK CHANGE

$22.22

MARKET CAP

109.983 M

YIELD

N/A

SHARES OUTSTANDING

65.466 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.79

PUBLIC FLOAT

AVERAGE 10 VOLUME

$293,745

AVERAGE 30 VOLUME

$265,431

Company detail

CEO: Joseph P. Hagan
Region: US
Website: regulusrx.com
Employees: 30
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Regulus Therapeutics Inc. engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

RGLS - Regulus Therapeutics Inc.